8月25日，上交所发布关于国泰海通证券股份有限公司2025年面向专业投资者公开发行公司债券（第四 期）（品种一）上市的公告。 依据《上海证券交易所公司债券上市规则》等规定，上交所同意国泰海通证券股份有限公司2025年面向 专业投资者公开发行公司债券（第四期）（品种一）于2025年8月26日起在上交所上市，并采取匹配成 交、点击成交、询价成交、竞买成交、协商成交交易方式。该债券证券简称为"25GTHT07"，证券代码 为"243544"。根据中国结算规则，可参与质押式回购。 来源：金融界 ...

Group 1 - The A-share market has reached 3800 points for the first time in ten years, with most brokerages believing that the internal and external fundamentals and liquidity conditions do not present significant bearish factors, supporting a continued upward trend in the market [1][9] - Citic Securities indicates that the current market rally is primarily driven by institutional investors rather than retail investors, emphasizing the importance of focusing on industry trends and performance rather than merely liquidity [2] - Guotai Junan Securities expresses optimism about the A-share market, citing multiple factors such as capital market reforms and improved risk appetite, which are expected to support the performance of Chinese assets [3] Group 2 - Galaxy Securities warns of potential increased volatility in the A-share market as it enters an acceleration phase, despite a generally positive mid-term outlook [4][6] - Zheshang Securities advises investors to ignore short-term fluctuations and focus on medium-term strategies, suggesting to increase positions near key support levels [10][11] - Xinyi Securities highlights the importance of identifying low-position opportunities in technology growth sectors while also considering cyclical sectors with growth potential [12] Group 3 - Huatai Securities notes that the consensus on the upward trend in the market is strengthening, driven by improvements in domestic fundamentals and liquidity [7][8] - The market is expected to maintain its strength until early September, with a shift in focus from short-term momentum to mid-term developments post-September [6] - The overall sentiment in the market remains bullish, with a focus on sectors such as AI, innovative pharmaceuticals, and military industries as key strategic allocations [8][13]

国泰海迪址芬 研究所 X 2025年前多年生生产 8月18、19、25、26日全天 9:00-17:40- 8月25日 (周 周期篇 刘 有色立版 联席首席分析 石油化工 煤炭开展 The Brun 女 公用事业 #分析 澳 Ein 学朋子 海 本 8 期货首席 画區館前 时间安排: 8月18、19、25、26日全天 9:00-17:40 | 8月25日周- | 周期篇 | | --- | --- | | 9:00-9:45 | 非金属类建材研究 | | 9:45-10:30 | 有色金属研究 | | 10:30-11:15 | 公用事业研究 | | 11:15-12:00 | 钢铁研究 | | 13:00-13:45 | 建筑工程研究 | | 13:45-14:30 | 基础化工研究 | | 14:30-15:15 | 交通运输研究 | | 15:15-16:00 | 煤炭开采研究 | | 16:00-16:45 | 石油化工研究 | | 16:45-17:30 | 房地产研究 | *表格更新于2025年8月7日 上海-黄浦区中山南路888号 . . . . . . 本订阅号所载内容仅面向国泰海通证券研究服 ...

Core Viewpoint - The company plans to utilize part of its temporarily idle raised funds for cash management to improve fund efficiency and increase returns for the company and its shareholders [6][9][10]. Summary by Sections Fundraising Overview - The company raised a total of RMB 75,880.00 million from its initial public offering (IPO) in August 2020, with a net amount of RMB 68,955.19 million after deducting issuance costs [1]. - In November 2023, the company raised RMB 18,830.26 million through a targeted issuance of shares, resulting in a net amount of RMB 18,342.53 million after expenses [2]. Investment Projects - The company disclosed that the funds from the IPO were allocated to a high-precision small power testing power supply and fuel cell, power semiconductor testing equipment production base construction project, with a planned use of RMB 27,646.23 million [3]. - The company has excess funds of RMB 41,308.96 million from the IPO, with plans to allocate the surplus to various projects, including a semiconductor testing and intelligent manufacturing equipment industrial park project [3][4]. Cash Management of Idle Funds - The company intends to use up to RMB 23,000 million of temporarily idle raised funds for cash management, with RMB 20,000 million from the IPO and RMB 3,000 million from the 2023 issuance [7][10]. - The cash management will involve investing in low-risk, high-liquidity financial products, ensuring that the funds are not used for non-raising purposes [7][8]. Board Approval and Compliance - The board of directors approved the cash management plan on August 22, 2025, ensuring that it does not affect the progress of investment projects or the safety of the raised funds [10]. - The company has complied with relevant regulations and internal policies regarding the management and use of raised funds, ensuring that the cash management does not alter the intended use of the funds [11].

Core Viewpoint - The company has completed the investment project of the "Semiconductor Testing and Intelligent Manufacturing Equipment Industrial Park" and plans to permanently supplement its working capital with the remaining raised funds, following the completion of the project and the approval of the board and shareholders [6][9][10]. Fundraising Overview - The company raised a total of RMB 758.8 million from its initial public offering, with a net amount of RMB 689.55 million after deducting issuance costs [1]. - The company established a special account for the management and use of the raised funds, ensuring compliance with regulatory requirements [2]. Investment Project Details - The company committed to invest RMB 276.46 million in the "High-Precision Small Power Testing Power Supply and Fuel Cell, Power Semiconductor Testing Equipment Production Base Construction Project" [2]. - The actual net amount raised was RMB 689.55 million, resulting in an excess of RMB 413.09 million after the planned investment [3]. Use of Excess Funds - The company decided to use RMB 120 million of the excess funds to permanently supplement working capital, which constitutes approximately 29.05% of the total excess funds [3][4]. - The remaining excess funds will be allocated to the "Semiconductor Testing and Intelligent Manufacturing Equipment Industrial Park Project," with a total investment of RMB 450 million, of which RMB 300 million will come from excess funds [4][5]. Project Completion and Surplus Funds - As of July 31, 2025, the project has completed its main construction and acceptance work, leading to the decision to conclude the project [6]. - The expected surplus funds amount to RMB 168.27 million, which includes interest and investment income, and will be used to permanently supplement working capital [8][9]. Impact on Company Operations - The decision to conclude the project and use surplus funds for working capital is aligned with the company's operational needs and long-term development strategy, enhancing cash flow and resource allocation [9][10]. - The company will maintain the special account for raised funds until all pending payments are settled, ensuring compliance with regulatory requirements [9]. Approval Process - The board of directors approved the proposal to conclude the investment project and use surplus funds on August 22, 2025, which will also require shareholder approval [10]. - The sponsor institution has confirmed that the decision complies with relevant regulations and is in the best interest of all shareholders [10][11].

Core Viewpoint - The article emphasizes the commitment of Guotai Haitong to social responsibility and rural revitalization through various initiatives and partnerships, showcasing its role as a leading financial enterprise in promoting sustainable development and community welfare [1][12][20]. Group 1: Initiatives and Achievements - Since 2016, Guotai Haitong has integrated political, economic, and social responsibilities, actively responding to national rural revitalization strategies, and has established a "five-in-one" assistance model [1]. - The company has completed a merger and reorganization, increasing the number of supported counties to 10, and held a significant public welfare event focused on rural revitalization [1][20]. - Guotai Haitong has built a comprehensive educational support system, having established six Hope Schools and engaged in various educational initiatives [3][7]. Group 2: Community Engagement and Support - The company has implemented projects like "Love Reading" and "Love Health" in Xinjiang, promoting cultural development and community cohesion [3]. - Employees of Guotai Haitong have taken active roles in rural areas, developing innovative sales models for agricultural products and enhancing local economies [4][5]. - The establishment of the "Rural Revitalization Special Fund" with an initial scale of 10 million yuan aims to empower local industries and support sustainable development [24]. Group 3: Collaborative Efforts - Guotai Haitong collaborates with various partners, including government and educational institutions, to enhance rural development and social welfare projects [12][15]. - The company has initiated the "Love Lunch" project and other health insurance initiatives in partnership with different organizations to support local communities [15][16]. - The "818" event has been transformed into a social cultural festival, reflecting the company's commitment to social responsibility and community engagement [26].

Core Viewpoint - The article discusses the results of the New Fortune Best Analyst Awards, highlighting the top research institutions and their rankings across various sectors, emphasizing the importance of enhancing the quality of research in the Chinese securities industry [31]. Group 1: Rankings of Research Institutions - The top research institutions in the overall category are: 1. GF Securities 2. Industrial Securities 3. Changjiang Securities 4. Shenwan Hongyuan Securities 5. Guosheng Securities [18]. - In the best industry research team category, the rankings are: 1. Changjiang Securities 2. GF Securities 3. Guotai Junan Securities 4. Industrial Securities 5. Shenwan Hongyuan Securities [20]. Group 2: Sector-Specific Rankings - In the financial engineering sector, the top institutions are: 1. Changjiang Securities 2. Industrial Securities 3. Guosheng Securities 4. GF Securities 5. Shenwan Hongyuan Securities [4]. - For the non-banking financial sector, the leading institutions are: 1. Guotai Junan Securities 2. GF Securities 3. Dongwu Securities 4. Changjiang Securities 5. Industrial Securities [5]. Group 3: Additional Sector Rankings - In the food and beverage sector, the top institutions are: 1. Changjiang Securities 2. GF Securities 3. Guotai Junan Securities 4. Huachuang Securities 5. Huaxi Securities [6]. - For the healthcare sector, the leading institutions are: 1. Industrial Securities 2. Tianfeng Securities 3. Guosheng Securities [6]. Group 4: Overall Impact and Purpose - The New Fortune Best Analyst Awards aim to promote the improvement of the research level in the Chinese securities industry, advocating for a professional standard that combines ethics and talent, contributing positively to the development of a modern capital market in China [31].

国泰海通证券股份有限公司 关于中巨芯科技股份有限公司 首次公开发行部分战略配售限售股上市流通的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 中巨芯科技股份有限公司（以下简称"中巨芯"或"公司"）首次公开发行股票 并在科创板上市及持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》等法律法规的相关规定，对中巨芯首次公开发行 部分战略配售限售股上市流通事项进行了核查，核查情况及核查意见如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2023 年 6 月 13 日出具的《关于同意中巨芯 （证监许可〔2023〕1278 号）， 科技股份有限公司首次公开发行股票注册的批复》 同意公司首次公开发行股票的注册申请，并经上海证券交易所同意，公司首次向 社会公开发行人民币普通股（A 股）股票 369,319,000 股，并于 2023 年 9 月 8 日 在上海证券交易所科创板上市，发行后公司总股本为 1,477,276,000 股，其中有 限售条件流通股 1,215 ...

国泰海通证券股份有限公司 关于上海奥浦迈生物科技股份有限公司 调整2025年度部分日常关联交易预计额度的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）首次公开 发行股票并在科创板上市持续督导的保荐机构，根据《证券发行上市保荐业务 管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上 市公司自律监管指引第 1 号——规范运作》等相关法律、法规和规范性文件的 规定，对奥浦迈调整 2025 年度部分日常关联交易预计额度的的事项进行了专项 核查，核查情况与意见如下： 一、本次日常关联交易执行及调整情况 公司于 2025 年 4 月 14 日召开第二届董事会第八次会议、第二届监事会第 七次会议以及第二届董事会独立董事专门会议第二次会议分别审议通过了《关 于预计 2025 年度日常关联交易的议案》，同意公司（含子公司）对 2025 年度日 常关联交易额度进行预计，涉及金额合计 446.00 万元，主要用于向相关关联方 购买原材料、向关联方销售商品以及接受关联方提供的技术服务。关联董事肖 志华、张俊杰回避表决，获 ...

国泰海通证券股份有限公司 关于上海奥浦迈生物科技股份有限公司 首次公开发行部分限售股上市流通的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）首次公开 发行股票并在科创板上市持续督导的保荐机构，根据《证券发行上市保荐业务管 理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》等法律法规的相关规定，对奥浦迈首次 公开发行部分限售股上市流通事项进行了核查，核查情况及核查意见如下： 一、本次上市流通的限售股类型 经中国证券监督管理委员会（以下简称"中国证监会"）于 2022 年 6 月 13 日出具的《关于同意上海奥浦迈生物科技股份有限公司首次公开发行股票注册的 批复》（证监许可〔2022〕1232 号），同意上海奥浦迈生物科技股份有限公司 （以下简称"奥浦迈"或者"公司"）首次公开发行股票的注册申请，并经上海证券 交易所同意，公司首次向社会公众公开发行人民币普通股 2,049.5082 万股，并于 本为 8,198.0328 万股，其中，有限售条件流通股 6,50 ...